Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 112

Results For "clinic"

3637 News Found

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer
Clinical Trials | October 22, 2025

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer

The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy


Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders
R&D | October 22, 2025

Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders

Contera Pharma will receive an upfront payment and full research funding for each target under investigation


Roche presents positive phase III data for vamikibart in uveitic macular edema
Clinical Trials | October 22, 2025

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME


AbbVie's Rinvoq beats Humira in key arthritis trial
Clinical Trials | October 22, 2025

AbbVie's Rinvoq beats Humira in key arthritis trial

The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor


FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Drug Approval | October 21, 2025

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation


IKS Health announces generative AI platform built on Google cloud
Digitisation | October 18, 2025

IKS Health announces generative AI platform built on Google cloud

IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow


Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million
News | October 17, 2025

Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million

Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio


Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer
Clinical Trials | October 17, 2025

Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer

Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents


Healthium partners with US-based Tisgenx to bring cardiac innovations to India
News | October 17, 2025

Healthium partners with US-based Tisgenx to bring cardiac innovations to India

This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment


BASF’s Personal Care business launches Ameriflor Calm
R&D | October 16, 2025

BASF’s Personal Care business launches Ameriflor Calm

Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity